Search
SOLACI Congress
HomeFileStructural heart disease

Structural heart disease

View Category

Structural heart disease

Should We Treat Stroke Percutaneously in TAVR?

Since its inception, transcatheter aortic valve replacement (TAVR) has improved greatly. However, there still are five big...
solaci -
Learn More
Structural heart disease

Can We Discharge TAVR Patients the Same Day?

For over a decade, TAVR has been showing great benefits, but conduction abnormalities such as RBBB and...
solaci -
Learn More
Structural heart disease

TAVR in Bicuspid Patients: Are Outcomes the Same in Men and Women?

Bicuspid aortic valve stenosis (BAV) has not yet been analyzed in large, randomized studies, and TAVR in...
solaci -
Learn More
Structural heart disease

Balloon expandable vs Self-Expanding Valves: The Best Option for ViV-TAVR in Small Annuli

TAVR has consolidated as an increasingly valid alternative to treat failed surgical aortic valve bioprostheses.   One...
solaci -
Learn More
Structural heart disease

Surgical Bioprosthesis Deterioration: Is the Valve-in-Valve Technique a Good Option?

The use of surgical bioprostheses has significantly increased, and while they last 15 years or more, in...
solaci -
Learn More
Other

Left Atrial Appendage Closure Is Safe with the New Devices

Left atrial appendage closure (LAAC) in non-valvular atrial fibrillation with high risk of bleeding has shown promising...
solaci -
Learn More
Structural heart disease

MitraClip in Patients with COPD: a Valid Option

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease are associated to hospitalization and mortality.  When associated to severe...
solaci -
Learn More
Structural heart disease

Combination of Percutaneous Suture Devices after TAVR to Reduce Vascular Complications

Current use of transcatheter aortic valve replacement (TAVR) has increased in intermediate-risk patients and has even been...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

TAVR in Pure Native Aortic Regurgitation: Are Dedicated Devices Truly Superior?

Dr. Juan Manuel Pérez - 0
This systematic meta-analysis assessed the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation. The emergence of...

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy